Gemphire to Present at the Oppenheimer Annual Healthcare Conference and the H.C. Wainwright NASH Investor Event
Oppenheimer & Company 27th Annual Healthcare Conference | ||||||||
Date: | Tuesday, March 21 | |||||||
Time: | 3:20pm Eastern Time | |||||||
Location: | Track 3, Westin New York Grand Central Hotel. | |||||||
Webcast: | https://www.veracast.com/webcasts/opco/healthcare2017/18113422476.cfm | |||||||
H.C. Wainwright NASH Investor Event | ||||||||
Date: | Monday, April 3 | |||||||
Time: | 9:40am Eastern Time | |||||||
Location: | Versailles Room, St Regis Hotel, New York City. |
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemphire has initiated 3 clinical trials for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH. Please visit www.gemphire.com for more information.
Contact:Andrew McDonald , Ph.D.LifeSci Advisors, LLC (646) 597-6987Jeff Mathiesen , CFOGemphire Therapeutics Inc. (734)-245-1700